Home Duke University Press
 QUICK SEARCH:   [advanced]


     
  Home | Help | Feedback | Subscriptions | Archive | Search | Advance Publication


First published on March 30, 2009
Neuro Oncol 2009, DOI:10.1215/15228517-2008-123
This Article
Right arrow Advance Publication Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Kozak, K. R.
Right arrow Articles by Moody, J. S.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Social Bookmarking
 Add to CiteULike   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?
© Copyright 2009 by the Society for Neuro-Oncology

Received September 19, 2008
Accepted December 17, 2008

Clinical Investigations

Giant cell glioblastoma: A glioblastoma subtype with distinct epidemiology and superior prognosis

Kevin R. Kozak 1 John S. Moody 2*

1 Department of Human Oncology, University of Wisconsin School of Medicine and Public Health, Madison, WI
2 Division of Radiation Oncology, Moses Cone Regional Cancer Center, Greensboro, NC

* To whom correspondence should be addressed. E-mail: kozak{at}humonc.wisc.com.


   Abstract

Background: Giant cell glioblastoma (GC) is an uncommon subtype of glioblastoma multiforme (GBM). Consequently, the epidemiology, natural history and factors associated with outcome are not well defined.

Methods: Patients diagnosed with GC from 1988 to 2004 were identified in the Surveillance, Epidemiology and End Results (SEER) database. Outcomes were examined with Kaplan-Meier survival analysis and Cox models. For comparison, similar analyses were conducted for patients diagnosed with GBM.

Results: GC was identified in 1% of 16,430 patients diagnosed with either GC or GBM. Compared to GBM, GC showed similar gender and racial distributions. Likewise, tumor size and location were not significantly different between the two histologies. GC tended to occur in younger patients with a median age at diagnosis of 51 years compared to 62 years for GBM. Additionally, patients with GC were more likely to undergo complete resection compared to patients with GBM. For both histologies, young age, tumor size, extent of resection and the use of adjuvant RT were associated with improved survival. Cox modeling suggests the prognosis for GC is significantly superior to GBM (HR = 0.76, 95% CI 0.59-0.97) even after adjustment for factors impacting survival.

Conclusions: GC is an uncommon GBM subtype that tends to occur in younger patients. Prospective data defining optimal treatment for GC are unavailable; however, these retrospective findings suggest resection, as opposed to biopsy only, and adjuvant RT may improve survival. The prognosis of GC is superior to GBM and long-term survival is possible suggesting aggressive therapy is warranted.

Key Words: Giant cell, glioblastoma , radiation, SEER


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?





  Home | Help | Feedback | Subscriptions | Archive | Search | Advance Publication


Copyright 2009 by Society for Neuro-Oncology